[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"prostate\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:prostate":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,45,76,106,140,166,192],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":30,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":40,"leadSponsor":42,"locationsCount":4},"100645202","ai-technologies-for-enhanced-and-celerated-high-field-wb-mri-100645202",false,"NCT07678320","AI Technologies for Enhanced and Celerated High-Field WB-MRI","AITECH-MRI","Inclusion Criteria:\n\n* Consecutive adults (≥18 y.o.) admitted to the UO for W MRI for screening procedure.\n* Consecutive adult male patients (≥18 y.o.) admitted to the UO for WB-MRI for screening procedure and focus on prostate.\n\nExclusion Criteria:\n\n* refused to consent\n* claustrophobia\n* metal prosthesis potentially affecting image quality",true,"ALL","18 Years",{"count":20,"type":21},600,"ESTIMATED","OBSERVATIONAL","Single-center, cross-sectional observational study assessing the feasibility of advanced accelerated MRI sequences versus standard ones in terms of image quality, diagnostic reliability, and acquisition time.",[25,26,27,28,29],"Whole Body Imaging","Prostate","MRI","Lung","Vascular",[27,31,32,33,29],"Whole Body","Accelerated Imaging","Prostate Imaging","NOT_YET_RECRUITING","2026-06-25",{"date":37,"type":38},"2026-07-01","ACTUAL",{"date":37,"type":21},{"date":41,"type":21},"2029-05-01",{"name":43,"class":44},"IRCCS San Raffaele","OTHER",{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":49,"acronym":4,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":51,"minAge":18,"maxAge":4,"enrollmentInfo":52,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":54,"conditions":55,"keywords":60,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":4,"leadSponsor":72,"locationsCount":75},"100127142","collection-of-blood-from-patients-with-prostate-cancer-100127142","NCT00923221","Collection of Blood From Patients With Prostate Cancer","* INCLUSION CRITERIA:\n\nIndividuals 18 years of age and older are eligible.\n\nIndividuals with a diagnosis of prostate cancer are eligible.\n\nEXCLUSION CRITERIA:\n\nChildren are not eligible.","MALE",{"count":53,"type":21},1000,"Background:\n\n* It is not fully understood why prostate cancer in some men becomes androgen-independent (no longer responds to anti-androgen medication), but genetics likely plays an important role.\n* Genes contain the hereditary information that is passed down from parents to children. Although everyone has the same set of genes, individuals can have different forms of the same gene.\n* Differences in genes may explain, at least in part, why some people develop a more aggressive form of prostate cancer than others.\n\nObjectives:\n\n-To obtain blood samples from patients with prostate cancer to try to identify gene differences associated with progression to the androgen independent state.\n\nEligibility:\n\n-All participants participating in NCI prostate cancer protocols.\n\nDesign:\n\n* Participants with prostate cancer are evaluated in the NCI s Medical Oncology Clinic.\n* Blood samples are collected at the initial visit or at follow-up visits.\n* DNA (genetic material) and white blood cells are extracted from these samples to be used for genotyping and establishment of cell lines.\n* Gene variations are correlated with prostate cancer prognosis and prognostic indicators.",[56,57,58,59,26],"Cancer Of Prostate","Prostate Cancer","Prostatic Neoplasms","Metastatic Prostate Cancer",[61,58,62,63,64,65,57],"Genetic","Genotyping","Venipuncture","Polymorphism","Natural History","RECRUITING","2026-06-05",{"date":69,"type":38},"2026-06-08",{"date":71,"type":38},"2007-02-28",{"name":73,"class":74},"National Cancer Institute (NCI)","NIH",1,{"id":77,"slug":78,"hasResults":11,"nctId":79,"briefTitle":80,"officialTitle":81,"acronym":4,"eligibilityCriteria":82,"healthyVolunteers":11,"sex":51,"minAge":18,"maxAge":83,"enrollmentInfo":84,"targetDuration":4,"studyType":86,"phases":87,"briefSummary":89,"conditions":90,"keywords":91,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":104,"locationsCount":75},"100609910","phase-2-posluma-18f-rhpsma-73-pet-ct-for-pirads-23-lesions-100609910","NCT07220720","POSLUMA® (18F-rhPSMA-7.3) PET-CT for PIRADS 2\u002F3 Lesions","Inclusion of POSLUMA® ((18)F-rhPSMA-7.3) PET-CT Imaging Improves Diagnostic Accuracy of Clinically-Significant Prostate Cancer Diagnosis in Men With PIRADS 2 and 3 Lesions on MRI","Inclusion Criteria:\n\n1. The patient is willing to provide signed informed consent and is able to comply with all required study-related procedures, where safe and feasible.\n2. The patient is male and at least 18 years of age.\n3. The patient has not previously undergone a prostate biopsy.\n4. The patient underwent a pelvic mpMRI within the last 90 days for the detection of potential prostate cancer (Pca).\n5. The patient is a candidate for a targeted MRI\u002FUS biopsy and is scheduled to undergo the procedure. Only patients scheduled for a biopsy before recruitment will be considered candidates.\n6. The patient has PIRADS 2 and\u002For PIRADS 3 lesions detected by a board-certified radiologist.\n\nExclusion Criteria:\n\n1. Patients with a prior diagnosis of prostate cancer.\n2. Patients with any medical condition or circumstance that, in the investigator's opinion, could compromise the study data or prevent the patient from fulfilling the study requirements.\n3. Patients participating in another interventional clinical trial within the past 30 days.\n4. Patients with known hypersensitivity to the active substance or any excipients of flotufolastat F 18 PET-CT.","100 Years",{"count":85,"type":21},30,"INTERVENTIONAL",[88],"PHASE2","The goal of this study to determine if using the (18)F-rhPSMA-7.3 PET-CT scan can improve the ability to spot serious prostate cancer in patients who have uncertain MRI results. These uncertain results include MRI results that showed a PIRADS 2 or PIRADS 3 area on the prostate. The investigators want to find out if this new test is better to detect prostate cancer than just doing a biopsy based on MRI alone.",[26],[92,93,94,95,96],"prostate cancer","posluma","pirads 2","pirads 3","prostate biopsy","2026-04-09",{"date":99,"type":38},"2026-04-13",{"date":101,"type":38},"2025-11-04",{"date":103,"type":21},"2032-11-15",{"name":105,"class":44},"University of Florida",{"id":107,"slug":108,"hasResults":11,"nctId":109,"briefTitle":110,"officialTitle":111,"acronym":4,"eligibilityCriteria":112,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":113,"targetDuration":4,"studyType":86,"phases":115,"briefSummary":117,"conditions":118,"keywords":125,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":129,"lastUpdatePostDateStruct":130,"startDateStruct":132,"completionDateStruct":134,"leadSponsor":136,"locationsCount":139},"100625585","phase-1-phase-i-study-of-sys6043-in-patients-with-advancedmetastatic-solid-tumors-100625585","NCT07424547","Phase I Study of SYS6043 in Patients With Advanced\u002FMetastatic Solid Tumors","Phase I Dose Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of SYS6043 in Patients With Advanced\u002FMetastatic Solid Tumors","Inclusion Criteria:\n\nMajor:\n\n* Aged ≥18 years old (on the date of signing the ICF).\n* Advanced\u002Funresectable or metastatic solid tumors confirmed by histology or cytology, disease recurrence or progression during or after systemic standard of care, and should be intolerant of or have no available standard of care therapy.\n* Have at least one measurable lesion, according to the Response Evaluation Criteria in Solid Tumors (RECIST V1.1). Participants with metastatic castration-resistant prostate cancer (mCRPC) who have only metastases to bone will be evaluated through discussion with the sponsor's medical monitor, before determining whether they can be enrolled.\n* Expected life expectancy of ≥ 3 months.\n* ECOG performance status of 0-1 and no worsening of the score within 28 days prior to enrollment.\n* LVEF ≥ 50% as shown by ECHO or MUGA within 28 days prior to enrollment.\n\nExclusion Criteria:\n\nMajor:\n\n* Prior B7-H3 targeted therapy.\n* Previously received drug therapy with topoisomerase inhibitor antibody-drug conjugate (e.g., trastuzumab deruxtecan).\n* Symptomatic congestive heart failure (CHF) (New York Heart Association \\[NYHA\\] Class II-IV) or a history of severe arrhythmia requiring treatment.\n* History of myocardial infarction or unstable angina within 6 months prior to enrollment.\n* Based on the results of three 12-lead electrocardiogram (ECG) examinations, the mean QT interval (QTcF) corrected by the Fridericia formula for both males and females is prolonged to \\>470 ms.\n* Unable or unwilling to discontinue concomitant medications known to prolong the QT interval.\n* History of interstitial lung disease (e.g., ILD\u002Fnon-infectious pneumonia requiring glucocorticoid treatment in the past), or currently have interstitial lung disease, or are suspected to have such diseases through imaging examinations during screening.\n* History of underlying lung disorders, including but not limited to pulmonary embolism within 3 months prior to the start of study treatment, severe asthma, severe COPD, restrictive pulmonary disease, and other clinically significant lung injuries or requiring supplemental oxygen.\n* Any autoimmune diseases, connective tissue disorders, or inflammatory diseases involving the lungs recorded or suspected during screening (e.g., rheumatoid arthritis, Sjögren's syndrome, sarcoidosis, etc.).\n* Presence of uncontrolled infection requiring intravenous injection of antibiotics, antiviral drugs, or antifungal drugs.\n* Active and clinically significant bacterial, fungal, viral infection, or Hepatitis C infection at screening (HCV antibodies test positive and HCV-RNA levels higher than the lower limit of quantification or 1000 copies\u002FmL (whichever is lower); HIV antibody positive or syphilis antibody positive (with confirmation)..\n* HBsAg positive and HBV-DNA above the lower limit of quantification or 1,000 copies\u002FmL (500 IU\u002FmL) (whichever is lower). Liver tumor: For participants with liver metastases and HBV infection, HBV DNA must be \\\u003C2000 IU\u002FmL before the first dose. Participants who are HBsAg-positive and\u002For HBV DNA-positive should receive at least 2 weeks of anti-Hepatitis B virus treatment prior to the first dose and be willing to continue treatment during the study.\n* Lactating women (women who are willing to temporarily discontinue breastfeeding will also be excluded), or women confirmed to be pregnant by pregnancy test within 7 days prior to enrollment.\n* Presence of spinal cord compression or clinically active brain metastasis, and\u002For meningeal metastases, defined as untreated, symptomatic, or requiring corticosteroids or anticonvulsants.",{"count":114,"type":21},386,[116],"PHASE1","The goal of this clinical trial is to learn if investigational drug called SYS6043 works in adults with advanced or metastatic solid tumors that have spread or cannot be treated with standard therapies. The main goals of the study are to understand how safe SYS6043 is, what side effects it may cause, and what dose can be given safely. Researchers will also study how the drug moves through the body and whether the immune system reacts to it. In addition, the study will look for early signs that SYS6043 may help slow or shrink tumors and explore whether the amount of a tumor protein called B7-H3 is related to how well the treatment works.\n\nParticipants will:\n\n* Provide written informed consent\n* Undergo screening tests to ensure they are eligible for study treatment\n* Attend all required study visits and receive SYS6043 by intravenous infusion once every 3 weeks (Q3W), with 21 days as one treatment cycle until the study doctor determines that study treatment should be stopped based on how well a participant is doing on treatment.\n* Have safety follow-up (SFU), and long-term follow-up.\n* Be followed until progression.",[119,120,121,26,122,123,124],"Cancer","Solid Tumor Cancer","Advanced Metastatic Cancer","Small Cell Lung Cancer","Ovarian Cancer","Breast Cancer",[126,127,128,92],"ovarian cancer","breast cancer","small cell lung cancer","2026-04-06",{"date":131,"type":38},"2026-04-07",{"date":133,"type":38},"2026-03-03",{"date":135,"type":21},"2030-04",{"name":137,"class":138},"Conjupro Biotherapeutics, Inc.","INDUSTRY",5,{"id":141,"slug":142,"hasResults":11,"nctId":143,"briefTitle":144,"officialTitle":144,"acronym":4,"eligibilityCriteria":145,"healthyVolunteers":11,"sex":51,"minAge":146,"maxAge":4,"enrollmentInfo":147,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":149,"conditions":150,"keywords":152,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":157,"lastUpdatePostDateStruct":158,"startDateStruct":160,"completionDateStruct":162,"leadSponsor":164,"locationsCount":75},"100594508","feasibility-and-safety-of-a-single-working-element-for-bipolar-and-laser-enucleation-in-prostate-surgery-a-prospective-study-100594508","NCT07020364","Feasibility and Safety of a Single Working Element for Bipolar and Laser Enucleation in Prostate Surgery: A Prospective Study","Inclusion Criteria:\n\n* Diagnosed with benign prostatic hyperplasia (BPH) requiring surgical intervention.\n* Prostate volume ≥40 cc (as assessed by transrectal ultrasound).\n* No prior history of prostate cancer.\n\nExclusion Criteria:\n\n* Patients with ongoing urinary tract infections.\n* Prior prostate surgeries.\n* Coagulation disorders or patients on long-term anticoagulation therapy.\n* Known urethral strictures or other anatomical abnormalities complicating endoscopic procedures.","50 Years",{"count":148,"type":21},60,"A prospective feasibility study would be a practical first step, focusing on real-time assessment and ensuring the new working element's integration is safe and effective before broader clinical trials.",[26,151],"BPH (Benign Prostatic Hyperplasia)",[153,154,155,156],"laser enucleation","bipolar enucleation","BPH","prostate","2025-06-04",{"date":159,"type":38},"2025-06-13",{"date":161,"type":38},"2024-10-01",{"date":163,"type":21},"2025-11-01",{"name":165,"class":44},"Menoufia University",{"id":167,"slug":168,"hasResults":11,"nctId":169,"briefTitle":170,"officialTitle":171,"acronym":4,"eligibilityCriteria":172,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":173,"targetDuration":4,"studyType":86,"phases":175,"briefSummary":177,"conditions":178,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":183,"lastUpdatePostDateStruct":184,"startDateStruct":186,"completionDateStruct":188,"leadSponsor":190,"locationsCount":75},"100576780","enhanced-recovery-after-urologic-surgery-100576780","NCT06789744","Enhanced Recovery After Urologic Surgery","Enhanced Recovery After Urologic Surgery: a Prospective Observational Study Comparing Regional with Conventional Anesthetic Techniques","Inclusion Criteria:\n\n* any age.\n* American Society of Anesthesiologists (ASA) physical status classification of I-III.\n* undergo urological surgery.\n* receive one of the following analgesic techniques: epidural analgesia (EA), paravertebral block (PVB), transversus abdominis plane (TAP) block, intravenous patient-controlled analgesia (PCA), or intrathecal morphine.\n* provided voluntary informed consent.\n\nExclusion Criteria:\n\n* a bleeding disorder or coagulopathy.\n* infection at the intended puncture site or systemic infection.\n* a known allergy to local anesthetics.\n* spinal deformity or spinal injury.\n* a psychiatric disorder that could impair their ability to cooperate with the study protocol.\n* pregnant or breastfeeding.\n* severe cardiovascular or pulmonary dysfunction.\n* chronic opioid use (defined as \\>1 month) at high doses.",{"count":174,"type":21},150,[176],"NA","This clinical trial aims to investigate the analgesic efficacy of several perioperative pain management strategies-specifically, epidural analgesia, paravertebral blockade, transversus abdominis plane (TAP) block, intravenous patient-controlled analgesia (PCA), and intrathecal morphine-in patients undergoing a range of urological procedures. These procedures include pediatric circumcision, hydrocelectomy, inguinal hernia repair, renal cyst excision, and transurethral resection of the prostate. The trial will also evaluate the safety profiles of two specific local anesthetics, liposomal bupivacaine and ropivacaine. The primary research question is whether these different analgesic techniques reduce postoperative opioid requirements in patients undergoing urological surgery. A secondary question explores the adverse events associated with the use of liposomal bupivacaine and ropivacaine in this population.\n\nParticipants will be:\n\nUrological surgery patients undergoing one of the aforementioned procedures. These participants will be randomized to receive one of the following pain management modalities: epidural analgesia, paravertebral blockade, TAP block, intravenous PCA, or intrathecal morphine. Patient assessments will be conducted in the post-anesthesia care unit (PACU) and at 2, 6, 12, and 24 hours postoperatively. Outcome measures will include: Numeric Rating Scale (NRS) pain scores, total postoperative analgesic consumption, recovery status, patient satisfaction, and time to return of bowel function.",[179,180,181,182,26],"Circumcision","Hydrocelectomy","Hernia","Renal Cyst","2025-01-22",{"date":185,"type":38},"2025-01-24",{"date":187,"type":21},"2025-02-01",{"date":189,"type":21},"2025-05-20",{"name":191,"class":44},"Xiaguang Duan",{"id":193,"slug":194,"hasResults":11,"nctId":195,"briefTitle":196,"officialTitle":197,"acronym":198,"eligibilityCriteria":199,"healthyVolunteers":11,"sex":51,"minAge":4,"maxAge":4,"enrollmentInfo":200,"targetDuration":201,"studyType":22,"phases":4,"briefSummary":202,"conditions":203,"keywords":204,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":213,"lastUpdatePostDateStruct":214,"startDateStruct":216,"completionDateStruct":218,"leadSponsor":220,"locationsCount":4},"100575425","focal-therapy-in-localized-prostate-cancer-a-prospective-registry-100575425","NCT06772116","Focal Therapy in Localized Prostate Cancer: a Prospective Registry","Jupiter Registry: Prospective Registry for Patients Undergoing Focal Therapy for Localized Prostate Cancer","JR","Inclusion Criteria:\n\n* Patients with intermediate risk PCa based on EAU risk groups with life expectancy \\> 10 years\n* Prior targeted + systematic biopsy using US-MRI fusion technique\n* Primary focal treatment (targeted or partial gland ablation) of PCa lesion(s) detected on mpMRI, where PCa ISUP 2 or 3 has been identified. PCa ISUP 1 outside the treatment areas is acceptable, regardless of volume.\n* Focal treatment was performed using one of the following energies: high-intensity focused ultrasound (HIFU), cryotherapy (CRYO), brachytherapy (BT), irreversible electroporation (IRE), focal laser ablation (FLA), vascular-targeted Photodynamic (VTP) and radiofrequency ablation (RFA) according to the country rules, approvals, and regulations of each country in which they are applied. The registry cannot be used as a clinical trial or post-marketing surveillance study of the technologies applied.\n* Free, informed and written consent\n\nExclusion Criteria:\n\n* Patients with intermediate risk treated with focal therapy without a previous targeted + systematic prostate biopsy with US-MRI fusion technique.\n* Primary focal treatment of PCa ISUP 2 or 3 in areas of prostate without evidence of lesions on MRI (MRI-invisible prostate cancer)\n* Patients with histological diagnosis of PCa with ISUP \\> 1 outside the areas of treatment\n* Primary whole gland treatments using ablative energy HIFU, cryotherapy, IRE, FLA, VTP and\u002For RFA\n* Primary subtotal\u002Ftotal treatments using ablative energy HIFU, cryotherapy, IRE, FLA, VTP and\u002For RFA\n* Life expectancy \\\u003C10 years\n* Previous treatment of PCa (excluded a period of Active Surveillance)\n* High risk PCa based on EAU risk groups.\n* Locally advanced PCa\n* Metastatic hormone-sensitive prostate cancer (mHSPC)\n* Metastatic castration-resistant prostate cancer (mCRPC)\n* Non-Metastatic Castration-Resistant Prostate Cancer (nmCRPC)",{"count":53,"type":21},"5 Years","The principal aim of the registry is to collect data on focal therapy (FT) for the treatment of intermediate-risk prostate cancer across Europe. Data will be gathered on cancer absence following treatment, survival rates, and the absence of disease failure or progression. Information will be collected from as many centers as possible over the next 5 years to enhance understanding of when focal therapy should be used, which energy types are most effective, and how patients respond to treatment, including its side effects and impact on quality of life.\n\nThis Europe-wide data collection will contribute to improving care by informing the development of enhanced national and international guidelines for prostate cancer treatment with focal therapy.",[26,57],[205,206,207,208,209,210,211,212],"Focal Therapy","HIFU","Cryotherapy","FLA","Focal Brachytherapy","IRE","VTP","RFA","2025-01-08",{"date":215,"type":38},"2025-01-13",{"date":217,"type":21},"2025-02",{"date":219,"type":21},"2032-02",{"name":221,"class":44},"Institut Mutualiste Montsouris"]